In another blow to big pharma, India's Supreme Court rejects Novartis's Glivec patent plea
India’s Supreme Court has issued its eagerly anticipated judgment in the long-running Glivec patent case. Upholding previous decisions, the court ruled that the country’s patent office was right to refuse a patent to Novartis for its anti-cancer…
To read more
Register for limited access
Register to receive our weekly newsletter and access two of our subscriber-only articles per month.
Register now
Subscribe and start reading now
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.
Subscribe now